Randomised controlled trials

A Phase III clinical trial comparing the safety and efficacy of Pradaxa® 150mg b.d. and 110mg b.d. vs warfarin in adult patients with NVAF and a risk of stroke. The primary outcome was stroke or systemic embolism1–3

Find out more

A randomised controlled trial comparing the safety of Pradaxa® (150mg b.d. or 110mg b.d.) dual therapy vs warfarin triple therapy in adult patients with NVAF who had undergone PCI with stenting4

Find out more

A randomised controlled trial comparing the safety of uninterrupted Pradaxa® 150mg b.d. vs uninterrupted warfarin in adult patients with NVAF undergoing catheter ablation5

Find out more

NVAF: non-valvular atrial fibrillation; PCI: percutaneous coronary intervention.